Ratings for GoodRx Holdings GDRX were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 5 | 8 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 4 | 6 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 1 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $8.36, with a high estimate of $14.00 and a low estimate of $4.50. Surpassing the previous average price target of $7.05, the current average has increased by 18.58%.
Diving into Analyst Ratings: An In-Depth Exploration
In examining recent analyst actions, we gain insights into how financial experts perceive GoodRx Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Stan Berenshteyn | Wells Fargo | Announces | Overweight | $10.00 | - |
| Sean Dodge | RBC Capital | Maintains | Sector Perform | $8.00 | - |
| Stan Berenshteyn | Wells Fargo | Raises | Equal-Weight | $7.50 | $6.00 |
| Eric Sheridan | UBS | Raises | Neutral | $8.00 | $5.00 |
| Sean Dodge | RBC Capital | Raises | Sector Perform | $8.00 | $7.00 |
| Eric Sheridan | Goldman Sachs | Raises | Neutral | $7.50 | $6.50 |
| Jailendra Singh | Truist Securities | Raises | Hold | $8.00 | $7.50 |
| Charles Rhyee | TD Cowen | Raises | Outperform | $14.00 | $12.00 |
| Lisa Gill | JP Morgan | Raises | Overweight | $10.00 | $7.00 |
| Steve Valiquette | Barclays | Raises | Overweight | $9.00 | $8.00 |
| Michael Cherny | Leerink Partners | Announces | Outperform | $8.00 | - |
| Sean Dodge | RBC Capital | Raises | Sector Perform | $7.00 | $5.00 |
| Jailendra Singh | Truist Securities | Raises | Hold | $7.50 | $5.50 |
| Michael Cherny | B of A Securities | Lowers | Underperform | $4.50 | $8.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to GoodRx Holdings. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GoodRx Holdings compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of GoodRx Holdings's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into GoodRx Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on GoodRx Holdings analyst ratings.
Get to Know GoodRx Holdings Better
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
GoodRx Holdings's Financial Performance
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining GoodRx Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.81% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: GoodRx Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -13.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): GoodRx Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.15%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): GoodRx Holdings's ROA excels beyond industry benchmarks, reaching -1.57%. This signifies efficient management of assets and strong financial health.
Debt Management: GoodRx Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.93, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
